前梯度蛋白2与前梯度蛋白3在卵巢癌诊治中的研究进展  

Progress of anterior gradient protein 2 and anterior gradient protein 3 in the diagnosis and treatment of ovarian cancer

作　　者：张晓蕾 张素伟 冯彦丽[2] Zhang Xiaolei;Zhang Suwei;Feng Yanli(Clinical College,Jining Medical University,Jining 272013,China;Department of Gynecology,Affiliated Hospital of Jining Medical University,Jining 272013,China)

机构地区：[1]济宁医学院临床医学院,济宁272013 [2]济宁医学院附属医院妇科,济宁272013

出　　处：《肿瘤研究与临床》2023年第1期77-80,共4页Cancer Research and Clinic

摘　　要：卵巢癌在妇科恶性肿瘤中居第3位,但其病死率却高居首位,虽然近年来在PARP抑制剂治疗方面取得了进展,但卵巢癌预后仍然较差。前梯度蛋白2(AGR2)可能是卵巢癌早期诊断的标志物,并且AGR2的表达提示卵巢癌的预后较好;而AGR3可能用于鉴别高级别与低级别浆液性卵巢癌,但其对预后的影响尚无定论。AGR2与AGR3可能是卵巢癌的治疗靶点。文章对AGR2与AGR3在卵巢癌诊治中的研究进展进行探讨。Ovarian cancer ranks the third among gynecological malignancies,while its mortality rate is the highest.Even though recent treatment progress has been made after using PARP inhibitors,the prognosis is still poor.Anterior gradient protein 2(AGR2)may be a marker for early diagnosis of ovarian cancer,and the expression of AGR2 suggests that the prognosis of ovarian cancer is better.However,Anterior gradient protein 3(AGR3)could be used to differentiate high-grade and low-grade ovarian cancer,but its influence on prognosis is still controversial.AGR2 and AGR3 may be therapeutic targets for ovarian cancer.This article introduces the research progress of AGR2 and AGR3 in the diagnosis and treatment of ovarian cancer.

关 键 词：前梯度蛋白2 前梯度蛋白3 卵巢肿瘤 诊断 预后 治疗 

分 类 号：R737.31[医药卫生—肿瘤]